pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·6h ago·1 min read
save

US releases $600M pledged to global vaccine alliance Gavi after year‑long delay

Jul 29, 2026·read at Endpoints ↗DealPositive

The United States has released the $600 million it pledged to Gavi, the global vaccine alliance.

The funds had been held in limbo for about a year before the Treasury completed the transfer.

Senator Susan Collins, chair of the Senate Foreign Relations Committee, highlighted the importance of the funding for expanding vaccine access in low‑income countries.

The disbursement fulfills the U.S. commitment made earlier and supports Gavi’s efforts to procure and distribute vaccines worldwide.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “US releases $600M in funding for global health group Gavi”

read at Endpoints ↗
80 words · retrieved 6h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 5h agoFTC sues Hims for sharing sensitive health information, billing practicesEndpoints
  • 7h agoUpdated: FDA adcomm votes down Capricor's DMD therapy over efficacyEndpoints
  • 8h agoTeva is confident it has time to brace for tariffs on non-US genericsEndpoints
  • 8h agoNYU's Neil Vasan departs as acting chair of FDA's cancer drug advisory panelEndpoints
  • 10h agoAtea's hep C pill equal to Gilead's; AbCellera inks second deal in two monthsEndpoints